 CAMBRIDGE, England BOSTON--BUSINESS WIRE--Bicycle Therapeutics plc NASDAQ: BCYC, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide Bicycle technology, today announced progress updates for its wholly owned, next-generation Bicycle Toxin Conjugates BTCs targeting oncological indications, as well as its novel, fully synthetic Bicycle tumor-targeted immune cell agonists TICAsTM. We are excited to start 2021 by an 